SBIR-STTR Award

Bacterial-Induced Sepsis: a New Treatment Strategy
Award last edited on: 3/21/2013

Sponsored Program
SBIR
Awarding Agency
NIH : NIAID
Total Award Amount
$3,745,316
Award Phase
2
Solicitation Topic Code
856
Principal Investigator
Sharon L McCoy

Company Information

13therapeutics Inc (AKA: Gene Targeted Delivery Inc~Targeted Gene Delivery Inc)

4640 Sw Macadam Avenue Suite 200d
Portland, OR 97239
   (503) 525-4887
   info@13therapeutics.com
   www.13therapeutics.com
Location: Single
Congr. District: 03
County: Multnomah

Phase I

Contract Number: 1R43AI065000-01A1
Start Date: 3/1/2006    Completed: 8/31/2007
Phase I year
2006
Phase I Amount
$99,244
Sepsis, a disease with increasing morbidity and mortality, results from an uncontrolled inflammatory immune response initiated by the interaction of bacteria or bacterial components with host Toll-like receptors (TLRs). Bacterial-induced sepsis is associated with production of proinflammatory cytokines, expression of cell adhesion molecules, and induction of cell apoptosis. Lipopolysaccaride (IPS) has been identified as a critical bacterial component in the pathogenesis of gram-negative sepsis. Current treatments focus on antibiotics for controlling infection and intensive care support for associated multi-organ failure. New treatment options are needed that address both the inflammatory response and the associated cell apoptosis. We have recently identified and characterized a peptide, derived from the immunoregulatory A52R vaccinia virus protein, that i) inhibits the in vitro secretion of proinflammatory cytokines in response to a variety of TLR ligands, including LPS, ii) functions in vivo to significantly reduce bacterial-induced inflammation in a mouse model of middle ear inflammation, and iii) in preliminary in vitro studies reduces LPS-induced cell apoptosis. We propose in this Phase I study to test the feasibility of this peptide as a treatment to reduce both the inflammation and cell apoptosis seen in LPS-induced sepsis. Experiments will examine in vitro the peptide effect in limiting endothelial cell activation and apoptosis in response to LPS (specific aim #1) and the in vivo effectiveness of the peptide in a mouse model of LPS-induced sepsis (specific aim #2). If successful, these studies will provide evidence for continued assessment of the peptide as a new treatment strategy for gram-negative bacterial-induced sepsis. New treatment options are necessary for patients with bacterial-induced sepsis, a disease with increasing morbidity and mortality. We have identified a novel therapeutic peptide that has demonstrated significant effects in the laboratory and will now be tested in an animal model of sepsis. If successful, these studies will provide the foundation for continued assessment of this peptide as a new treatment strategy for sepsis

Phase II

Contract Number: 2R44AI065000-02
Start Date: 3/1/2006    Completed: 5/31/2009
Phase II year
2007
(last award dollars: 2013)
Phase II Amount
$3,646,072

Sepsis is a disease with increasing morbidity and mortality that results from an uncontrolled inflammatory immune response initiated by the interaction of bacteria or bacterial components with host Toll-like receptors (TLRs). Bacterial-induced sepsis is associated with production of proinflammatory cytokines, expression of cell adhesion molecules, tissue damage, and in some cases death. Lipopolysaccaride (LPS) has been identified as a critical bacterial component in the pathogenesis of gram-negative sepsis. Current treatments focus on antibiotics for controlling infection and intensive care support for associated multi-organ failure. New treatment options are needed that address the unregulated inflammatory immune response. The A52R protein from vaccinia virus has been reported to inhibit production of proinflammatory cytokines in response to cell activation by a variety of TLR ligands. The protein was demonstrated to bind to intracellular signaling proteins common to TLRs. We have recently identified and characterized a peptide, termed P13, derived from the A52R protein, with similar properties as the parent protein. Studies conducted during the Phase I portion of this project demonstrated that peptide P13, i) inhibited the in vitro secretion of proinflammatory cytokines by endothelial cells and hepatocytes in response to LPS, ii) functioned in vivo to significantly reduce LPS-induced production of inflammatory mediators in the serum, and iii) enhanced survival in mice injected with LPS. The current Phase II SBIR proposal will expand these Phase I studies and define parameters for optimizing treatment with peptide P13 (specific aim #1), and provide a detailed assessment of the efficacy of peptide P13 in limiting inflammation and enhancing survival in endotoxin-induced sepsis (specific aim #2) and polymicrobial sepsis (specific aim #3). Establishing the efficacy of peptide P13 in both models of sepsis will provide a critical evaluation of the therapeutic potential of peptide P13. New treatment options are needed for patients with bacterial-induced sepsis, a disease with increasing morbidity and mortality. We have identified a novel anti-inflammatory peptide that has demonstrated feasibility to limit inflammation and disease development in an animal model of sepsis. Our current studies will provide a critical evaluation of the therapeutic potential of this peptide as a new treatment strategy for sepsis.

Thesaurus Terms:
Intracellular; Model; Secretion; Toll Like Receptor